When metastatic cancers are challenged with targeted agents almost invariably a subset of
cells insensitive to the drug emerges. As a result, in most instances, targeted therapies are …

When metastatic cancers are challenged with targeted agents, almost invariably a subset of
cells insensitive to the drug emerges. As a result, in most instances, targeted therapies are …

Colorectal cancer (CRC) arises by a continuous process of genetic diversification and clonal
evolution. Multiple genes and pathways have a role in tumor initiation and progression. The …

Cancer resistance evolution was presumed to result from either a pre-existing or acquired
mutation that survives treatment, re-populating the tumour following therapy. However, it …

Despite the continuous deployment of advanced treatment strategies, most disseminated
cancers remain fatal. Like species evolution, cancer is subject to the evolutionary processes …

The emergence of drug resistance limits the efficacy of targeted therapies in human tumors.
Strategies to prevent or overcome resistance are essential to design the next generation of …

Improvements in screening and preventive measures have led to an increased detection of
early stage colorectal cancers (CRC) where patients undergo treatment with a curative …

Tumour evolution, which results in the existence of multiple distinct populations of cancer
cells within the same tumour and the same patient, is increasingly appreciated to have a key …

Cancer is the leading cause of death worldwide. Despite improvements in diagnosis and
treatment over the past two decades, cancer continues to present a serious challenge to …

Cancer treatment is often aimed at achieving rapid, large, and sustained reductions in tumor
burden. Even when these strong responses are achieved, treatment frequently fails due to …